01 The pet diabetes care devices market is moderately exposed to supply chain disruptions due to its reliance on electronic components, sensors, medical-grade plastics, and specialized manufacturing processes. Disruptions in global logistics, semiconductor availability, and raw material supplies can delay the production and distribution of glucose monitoring devices, insulin delivery systems, and testing accessories, affecting product availability across key markets. These challenges also increase manufacturing costs, extend lead times, and create inventory imbalances, influencing veterinary clinics, distributors, and pet owners worldwide. The market is demonstrating a capacity-constrained recovery, supported by improving component availability, diversified supplier networks, and expanding production capabilities that are gradually restoring supply stability and meeting growing demand.
01 Growing Adoption of Continuous Glucose Monitoring in Companion Animals A key market trend is the increasing adoption of continuous glucose monitoring devices for diabetic pets as veterinary care shifts toward real-time and less invasive disease management. Pet owners and veterinarians are moving from traditional intermittent blood glucose testing to wearable monitoring systems that provide continuous glucose insights, improving treatment accuracy and reducing stress for animals. This transition supports personalized insulin management, early detection of glucose fluctuations, and better long-term disease control. For example, Zoetis offers CGM solutions that enable veterinarians to monitor glucose levels in diabetic dogs and cats more efficiently.
02 Rising Integration of Digital Pet Health Platforms with Diabetes Management The integration of pet diabetes care devices with digital health platforms enables remote monitoring and data sharing. Diabetes management is shifting from standalone devices to connected ecosystems that allow pet owners to track glucose readings, medication schedules, and health trends through mobile applications. This transition enhances treatment adherence, supports timely veterinary interventions, and improves overall disease management. For example, Abbott has expanded the use of its FreeStyle Libre technology in veterinary practice, allowing veterinarians to access continuous glucose data for improved diabetes management in pets.
01 The pet diabetes care devices market forecasts investments directed toward the development of continuous glucose monitoring systems, connected insulin delivery devices, and AI-enabled remote monitoring platforms for companion animals. Investment is also expected to support manufacturing expansion, product commercialization, veterinary digital health integration, and clinical validation of next-generation diabetes management technologies.In June 2026, ALR Technologies SG Ltd. signed a Letter of Intent to acquire CGM Medical Technology Singapore Pte. Ltd. in a transaction valued at USD 45 million in cash plus 200 million ALR common shares. The strategic investment is intended to strengthen the manufacturing and commercialization of the GluCurve Pet CGM, expanding the company's presence in the veterinary continuous glucose monitoring market.
01 Growing Pet Humanization and Increasing Veterinary Adoption of Continuous Glucose Monitoring Drives Market The increasing humanization of pets is driving demand for advanced diabetes care devices as owners invest more in preventive and chronic disease management. Pet owners increasingly prefer convenient home-monitoring technologies that improve treatment outcomes and simplify long-term care. This is accelerating adoption of connected glucose monitoring devices across veterinary practices.The growing clinical adoption of continuous glucose monitoring systems in veterinary medicine is driving demand for pet diabetes care devices by replacing conventional intermittent blood glucose testing. CGM enables veterinarians to monitor glucose fluctuations over several days without repeated blood sampling, improving insulin dose adjustments and reducing stress in diabetic pets. This shift is increasing demand for wearable sensors, readers, and diabetes monitoring software.
01 Requirement for Specific Glucose Calibration and Low Diagnosis Rate of Diabetes in Companion Animals Restrain Market Expansion Differences in glucose physiology between companion animals and humans restrain the adoption of pet diabetes care devices by increasing the need for species-specific calibration and validation. Many glucose monitoring technologies are originally designed for human use, requiring additional clinical validation before they can deliver reliable readings in dogs and cats. This limits regulatory approvals, slows the introduction of veterinary-specific devices, and reduces confidence among veterinarians in adopting newer monitoring technologies, thereby restraining market growth.The low diagnosis rate of diabetes in companion animals restrains the demand for pet diabetes care devices by limiting the number of pets receiving long-term glucose monitoring and treatment. Many cases remain undiagnosed because early symptoms such as increased thirst, weight loss, and frequent urination are often mistaken for normal aging or other health conditions. This delays treatment initiation and reduces the adoption of glucose monitoring devices and insulin management solutions, particularly in developing veterinary markets.
01 Expansion of Veterinary Telemedicine and Development of Veterinary-Specific Continuous Glucose Monitoring Systems Offer Growth Opportunities to Market Players The expansion of veterinary telemedicine is creating new opportunities for pet diabetes care device manufacturers by enabling remote glucose monitoring and digital disease management. Connected diabetes devices that automatically share glucose data with veterinarians support timely insulin adjustments without frequent clinic visits. For example, in 2025, Vetster expanded its telehealth platform across North America, increasing virtual chronic disease consultations, including diabetes management, creating greater demand for connected glucose monitoring devices integrated with remote veterinary care.The growing development of continuous glucose monitoring systems designed specifically for companion animals presents a significant opportunity for market participants. Unlike adapted human devices, veterinary-specific CGMs improve glucose measurement accuracy, sensor retention, and treatment compliance, encouraging broader clinical adoption. According to the American Veterinary Medical Association, more than 65 million US households own a dog and over 46 million own a cat, providing a substantial addressable population for dedicated veterinary diabetes monitoring technologies as diabetes diagnoses continue to increase.
01 Difficulty in Maintaining Continuous Device Wearability and Limited Availability of Veterinary Diabetes Specialists Hinders Market Growth Maintaining continuous wearability of diabetes monitoring devices remains a significant challenge, particularly in active dogs and cats. Companion animals frequently scratch, groom, swim, or engage in outdoor activities that can dislodge sensors before the intended monitoring period is completed. These interruptions reduce data continuity, require premature sensor replacement, and increase overall management complexity, creating challenges for both veterinarians and pet owners in achieving reliable long-term glucose monitoring.Successful use of continuous glucose monitoring systems requires accurate interpretation of glucose trends, insulin adjustments, and long-term treatment planning. The shortage of trained specialists creates inconsistencies in device utilization and clinical decision-making, slowing the adoption of advanced diabetes care technologies across general veterinary practices.